Biolife solutions reports second quarter 2025 financial results

Cell processing revenue of $23.0 million, up 28% over q2 2024 gaap gross margin of 62%  and non-gaap adjusted gross margin of 65% gaap net loss of $15.8 million, inclusive of a non-cash $15.5 million ipr&d expense, and non-gaap adjusted ebitda of $6.1 million or 24% of revenue raises full-year 2025 revenue guidance to $100.0 million - $103.0 million, and full-year 2025 cell processing revenue guidance to $91.0 million - $93.0 million conference call begins at 4:30 p.m. eastern time today bothell, wash.
BLFS Ratings Summary
BLFS Quant Ranking